Passage Bio, Inc. (PASG)
NASDAQ: PASG · IEX Real-Time Price · USD
0.900
+0.010 (1.10%)
At close: Jul 19, 2024, 4:00 PM
0.873
-0.027 (-3.00%)
Pre-market: Jul 22, 2024, 7:12 AM EDT
Passage Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Passage Bio stock have an average target of 9.00, with a low estimate of 5.00 and a high estimate of 13. The average target predicts an increase of 900.11% from the current stock price of 0.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2024.
Analyst Ratings
The average analyst rating for Passage Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +1,344.60% | May 15, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,455.73% | Mar 5, 2024 |
| Raymond James | Raymond James | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +455.62% | Nov 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +900.11% | Aug 8, 2023 |
| Raymond James | Raymond James | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +900.11% | May 12, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.07
from -1.86
EPS Next Year
-0.63
from -1.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 1.7M | 141.8M | 493.8M |
| Avg | n/a | n/a | 543,997 | 37.5M | 127.9M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 25,957.1% | 1,215.7% |
| Avg | - | - | - | 6,799.3% | 240.9% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.87 | -0.54 | -0.51 | -0.12 | 2.16 |
| Avg | -1.07 | -0.63 | -0.61 | -0.28 | 0.78 |
| Low | -1.23 | -0.74 | -0.69 | -0.43 | -0.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.